# 2026-20427: FDA Seeks Input on Trippy Ibogaine Trials for Addiction and PTSD

2026-20427, Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-10-06, effective Submit either electronic or written comments, data, or information by November 20, 2026.; PRIA reads it as touching household money (as of 2026-10-13).

- Canonical: https://policyrisk.com/federal-register/2026-20427
- As of: 2026-10-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20427
- Title: Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 63563
- Published: 2026-10-06
- Effective: Submit either electronic or written comments, data, or information by November 20, 2026.
- Comments close: 2026-11-20
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-13

## In one line

FDA Seeks Input on Trippy Ibogaine Trials for Addiction and PTSD

## Summary

The FDA is asking for public input on how to safely run early clinical trials for ibogaine, a drug being studied to help adults with opioid addiction and PTSD. The government is funding these trials and wants to make sure the study plans cover important safety and care details. Comments are open until November 20, 2026, so anyone interested can share their thoughts before the FDA finalizes its rules.

## Abstract

The Food and Drug Administration (FDA or the Agency) is describing the approaches it is considering for the design of early- phase clinical trials of ibogaine drug products and is opening a public docket to receive comments. The Department of Health and Human Services (HHS) is funding clinical development of ibogaine, and the first federally supported trials are expected to study ibogaine in adults with opioid use disorder (OUD) and adults with post-traumatic stress disorder (PTSD). FDA is building on the guidance for industry entitled "Psychedelic Drugs: Considerations for Clinical Investigations" by seeking comments, data, and information from the public on protocol elements relevant to ibogaine development--including dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules, and safety oversight, in part, because the Federal Government is funding work in this area. FDA will consider all information provided in response to this Request for Information (RFI) to inform whether and how these specific elements should be considered in its review of Investigational New Drug Applications (INDs) involving ibogaine.

## Effects PRIA read

- Federal funding and data sharing for ibogaine trials: benefit, medium. The Department of Health and Human Services is funding early clinical research on ibogaine through ARPA-H and the National Institute on Drug Abuse, and data from these federally funded programs will be made publicly available to investigators and sponsors. This support is intended to help kick-star…
- Initial dose cap and sequential dosing plan: benefit, medium. FDA's initial thinking for an early trial would limit individual doses to not exceed 10 mg/kg and use small, sequential dose-ascending groups with participants dosed one at a time. Dose increases for the next group would occur only after review by a safety review committee, a data and safety monito…
- Strict cardiac monitoring and inpatient care setting: benefit, medium. FDA envisions early ibogaine trials in an inpatient unit with continuous cardiac rhythm monitoring, a physician-led advanced cardiac life support team, a bedside defibrillator, emergency pacing, ventilator support, and monitoring that could last as long as 36 hours after dosing. At least two staff…
- Eligibility limits and exclusion criteria for participants: cost, medium. Potential participants could be limited to adults 18 to 55 years old and likely excluded if they have structural cardiovascular disease, a baseline QTcF of 430 ms or greater, abnormal heart rate or blood pressure, a history of seizures, psychosis, bipolar disorder, recent suicidal thoughts or behav…
- Medication restrictions before dosing: cost, medium. Before dosing, participants should stop medications that prolong the QTc interval, slow heart rate, interact with the CYP2D6 enzyme, or raise serotonin. Examples include opioid agonist medications (methadone and buprenorphine), antipsychotics, certain antiemetics, and selective serotonin reuptake i…
- Study stopping rules for serious events: benefit, low. Dosing should be paused for review if a participant has a sustained ventricular arrhythmia or seizure, a QTc prolongation above 500 ms that persists more than two days, new suicidal thoughts or lasting perceptual disturbances after acute effects, a death or serious adverse event possibly related to…
- Independent oversight and required expertise: cost, medium. FDA envisions that trials will have a safety review committee (SRC) and an independent data and safety monitoring board (DSMB) that include specialists such as a cardiologist, neurologist, psychiatrist, and biostatistician; trials enrolling people with opioid use disorder should also include an add…
- Genotyping and metabolizer-based enrollment: cost, low. Participants could be genotyped for CYP2D6 and trials may include only fast and intermediate metabolizers, with doses adjusted as needed, because CYP2D6 converts ibogaine to its active metabolite noribogaine.
- Product quality and CMC requirements for sponsors: cost, low. The ibogaine used in trials must be well characterized, include a certificate of analysis, and provide chemistry, manufacturing, and controls (CMC) information as required under 21 CFR 312.23(a)(7).

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-20427 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/06/2026-20427/design-and-safety-considerations-for-clinical-trials-involving-ibogaine-drug-products-request-for)
- [2026-20427 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-06/pdf/2026-20427.pdf)

## Related
- [Previous: 2026-20426, Request for Information: Nationwide Implementation of Prehospital Blood Transfu…](https://policyrisk.com/federal-register/2026-20426)
- [Next: 2026-20428, Privacy Act of 1974; System of Records](https://policyrisk.com/federal-register/2026-20428)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20427 (as of 2026-10-13).
